• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Cv rare disease

Quote






I completely agree! BMS is at risk of losing their cardiovascular representatives to companies that actually have dedicated cardiovascular specialty teams and offer competitive salaries and bonuses. They have been underpaying their CV team for promoting a drug for a rare disease for the past 3 years. Once Cytokinetics launches their drug, I anticipate that half of BMS's CV team will be aggressively recruited. It makes me wonder how BMS will respond—perhaps by offering a small retention bonus, more contest? They've already seen quality representatives leave over the past year due to low pay, unrealistic targets and goals, reps missing out on bonuses, and the challenges of promoting a drug for a rare condition.
 




anonymous said:
I completely agree! BMS is at risk of losing their cardiovascular representatives to companies that actually have dedicated cardiovascular specialty teams and offer competitive salaries and bonuses. They have been underpaying their CV team for promoting a drug for a rare disease for the past 3 years. Once Cytokinetics launches their drug, I anticipate that half of BMS's CV team will be aggressively recruited. It makes me wonder how BMS will respond—perhaps by offering a small retention bonus, more contest? They've already seen quality representatives leave over the past year due to low pay, unrealistic targets and goals, reps missing out on bonuses, and the challenges of promoting a drug for a rare condition.
Click to expand...
I agree totally!! Especially since they are bringing in new hires giving them rare disease starting salaries.
Already lost a lot to bridge bio
 




Like
anonymous said:
I agree totally!! Especially since they are bringing in new hires giving them rare disease starting salaries.
Already lost a lot to bridge bio
Click to expand...
So many open positions in CV. I love selling in in the rare disease space but all the changes to our customers is terrible as well. A true up in salary is needed very soon. We have so many good reps that will be pulled over to Cyto.
 




Salary true up is much needed! Territories changed it seems every 8 or 9 month's. Drs are confused who the rep is etc. Not sure why they still use ZS associates. I did hear dbms had input a bit.
The panic is real with camzyos for real.
 




Agreed, the panic and pressure is real with Camzyos!

DBMs provided their input, but ZS Associates still chose not to take it into account. The reason behind all these territory changes is that the goals and expectations are unrealistic and misaligned with the business. Additionally, some territories require over a six-hour drive just to cover them, making it difficult for representatives to conduct effective calls with a drug like Camzyos. Throughout the guidance call this morning, they repeatedly said, “I ask you…”. Well, CV team, we are asking to be fairly compensated for being a specialty sales force in the rare disease sector.

The writing is on the wall. I foresee the Community TAS salesforce will be having a similar call like our Zeposia UC colleagues this morning.
 












anonymous said:
12000 patients are on. What’s the panic. That’s nice growth.
How many zeposia reps were let go?
Click to expand...
It seems like you might be in denial or really buying into the narrative of our “growth”. We're falling short of our projected goals, which are extremely high, and many reps are struggling to earn their bonuses. They keep creating scenarios that don't reflect reality. If this drug is 1 in 500, the goals and expectations shouldn't be in double digits, especially without any Centers of Excellence in the territory. We're facing the same issues with IC and geographies like Zeposia, with changes happening every 5-6 months. BMS has struggled with their last four launches and seems to lack the expertise in launching rare disease and biologic drugs.
 








anonymous said:
Too many changes for any type of success and with holidays coming a lot of reps will be off too. No way to meet Camzyos goals.
Maybe UC Reps will roll in CV vacancies
Click to expand...
BMS has solid Cardiology reps. That is why you see so many being heavily recruited into other companies paying $40-50,000 grand more. True rare disease pay. Not to mention we have to still promote Eliquis which is still #5 in revenue in the US. So much money being brought in and we are not treated fairly. More will follow. Cyto will get a lot of rep from BMS or whatever company purchases them .)
 




anonymous said:
BMS has solid Cardiology reps. That is why you see so many being heavily recruited into other companies paying $40-50,000 grand more. True rare disease pay. Not to mention we have to still promote Eliquis which is still #5 in revenue in the US. So much money being brought in and we are not treated fairly. More will follow. Cyto will get a lot of rep from BMS or whatever company purchases them .)
Click to expand...
True. It takes special talent to read a PI to a medical professional with innumerable more years of eduction and experience than you.
 




anonymous said:
Too many changes for any type of success and with holidays coming a lot of reps will be off too. No way to meet Camzyos goals.
Maybe UC Reps will roll in CV vacancies
Click to expand...
DBMs will now have to choose between their Community reps seeking an IS opportunity, JNJ reps who have been selling against the competition for several years and likely have strong relationships, or BMS Zeposia reps who have just been displaced. The Community reps who have been here for 6-8 years or more will likely be the more cost-effective option, as they will be earning significantly less than the external candidates or the Zeposia reps. Immunology positions pay at least $30,000 more per year more than CV TAS.
 




anonymous said:
BMS has solid Cardiology reps. That is why you see so many being heavily recruited into other companies paying $40-50,000 grand more. True rare disease pay. Not to mention we have to still promote Eliquis which is still #5 in revenue in the US. So much money being brought in and we are not treated fairly. More will follow. Cyto will get a lot of rep from BMS or whatever company purchases them .)
Click to expand...
I completely agree! BMS still hasn't grasped the situation…there is a huge misconception. If they fairly compensated the sales team with appropriate pay for rare disease roles, they would likely be closer to achieving their unrealistic goals. The morale of the sales force is low when they're not meeting targets, earning money, or feeling valued. BMS really needs to align their Rare Disease Specialty Sales Force before the competition enters the market because most reps are just waiting to submit their resume.
 








anonymous said:
Morale is low. Community TAS and IS TAS jealousy over a few grand more IC.
Pay is not that of a rare disease job and most reps just waiting to get out of cv.
Click to expand...
I don’t believe this is about jealousy. The launch of Camzyos was mishandled by the company. It's unrealistic to expect one Salesforce to sell a complex product while anticipating another Salesforce to do the same, yet earn less in salary and bonuses. Some IS TAS rely on their CTAS representatives just to gain access to offices and meet with providers, but they aren't receiving the credit they deserve. While they might earn the district NPRx, if the district fails to meet its goals, the CTAS won't receive any bonus for their collaborative efforts. Additionally, with goals set so high that they seem unattainable, many IS TAS are missing out on bonus opportunities, while some CTAS with limited potential in their territories are benefiting from the efforts of other CTAS in their district without putting in the same level of effort during their workday. Ultimately, if the company aims for all representatives to function as Rare Disease Specialty reps, then all reps should be compensated equally, with realistic goals established and accountability enforced. The structure of this salesforce is completely flawed.
 




anonymous said:
Morale is low. Community TAS and IS TAS jealousy over a few grand more IC.
Pay is not that of a rare disease job and most reps just waiting to get out of cv.
Click to expand...
Morale is certainly low, and many reps are feeling frustrated and anxious about job security. Since the launch of Camzyos, CV has undergone changes every 6 months. It seems that the SLT is out of touch with what needs to be done. Now, they're merging the training division CV/IMM starting this Monday.
 




anonymous said:
Morale is certainly low, and many reps are feeling frustrated and anxious about job security. Since the launch of Camzyos, CV has undergone changes every 6 months. It seems that the SLT is out of touch with what needs to be done. Now, they're merging the training division CV/IMM starting this Monday.
Click to expand...
Cv/imm starting Monday? How is this going to work or make anything better?
 




Come on guys-
Eliquis is on its way out, xarelto goes generic in about a year- plans will make patients try xarelto first before Eliquis.
You’re fooling yourself if you don’t think so. This also means more layoffs folks.
 




anonymous said:
Cv/imm starting Monday? How is this going to work or make anything better
Click to expand...
I think they are referring to the post about training of CV/IMM coming together. It shouldn't be a concern. I don't think CV and IMMs are coming together and if they are, they should have never let Anthony Mancini go since that was his baby.
 




Top Bottom
Back
Quote